Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Schmid, Adrian ^a   Gianella, Sara ^a   von Wyl, Viktor ^a   Metzner, Karin J ^a   Scherrer, Alexandra U ^a   Niederöst, Barbara ^a   Althaus, Claudia F ^a   Rieder, Philip ^a   Grube, Christina ^a   Joos, Beda ^a   Weber, Rainer ^a   Fischer, Marek ^a   Günthard, Huldrych F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY INTERVENTION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; RNA SPLICING; RNA TRANSCRIPTION; VIRUS LOAD; VIRUS TRANSCRIPTION; BLOOD; DISEASE CARRIER; GENETIC TRANSCRIPTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POLYMERASE CHAIN REACTION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; DISEASE RESERVOIRS; HIV INFECTIONS; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; RNA, VIRAL; TRANSCRIPTION, GENETIC; VIRAL LOAD;

EID: 78149441721     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013310     Document Type: Article

References (73)

1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337: 734-739.
2. Opravil M, Cone RW, Fischer M, Vernazza P, Basseti S, et al. (2000) Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: A randomized trial of double versus triple therapy. J Acquir Immune Defic Syndr Hum Retrovirol 23: 17-25.
3. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, et al. (1997) Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 315: 1194-1199.
4. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
5. Stebbing J, Gazzard B, Douek DC (2004) Where does HIV live? N Engl J Med 350: 1872-1880.
6. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, et al. (2009) The challenge of finding a cure for HIV infection. Science 323: 1304-1307.
7. Dahl V, Josefsson L, Palmer S (2009) HIV reservoirs, latency, and reactivation: prospects for eradication. Antiviral Res 85: 286-294.
8. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291-1295.
9. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
10. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 94: 13193-13197.
11. Kaiser P, Joos B, Niederoest B, Weber R, Günthard HF, et al. (2007) Productive Human Immunodeficiency Virus 1 Infection in peripheral Blood Predominantely Takes Place in CD4/CD8 double negative T Lymphocytes. J Virol 81: 9693-9706.
12. Fischer M, Joos B, Niederost B, Kaiser P, Hafner R, et al. (2008) Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retrovirology 5: 107.
13. Zhang L, Chung C, Hu BS, He T, Guo Y, et al. (2000) Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest 106: 839-845.
14. Fischer M, Joos B, Wong JK, Ott P, Opravil M, et al. (2004) Attenuated and nonproductive viral transcription in lymphatic tissue of human immunodeficiency virus type 1 infected patients on potent antiretroviral therapy. J Infect Dis 189: 273-285.
15. Günthard HF, Havlir DV, Fiscus S, Zhang ZQ, Eron J, et al. (2001) Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 183: 1318-1327.
16. Anton PA, Mitsuyasu RT, Deeks SG, Scadden DT, Wagner B, et al. (2003) Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS 17: 53-63.
17. Markowitz M, Vesanen M, Tenner-Racz K, Cao Y, Binley JM, et al. (1999) The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 179: 527-537.
18. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, et al. (2004) Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200: 761-770.
19. Yukl S, Gianella S, Sinclair E, Epling L, Li Q, et al. (2010) Differences in HIV Burden and Immune Activation within the Gut of HIV+ Patients on Suppressive Antiretroviral Therapy. J Infect Dis: In press.
20. Barber SA, Gama L, Dudaronek JM, Voelker T, Tarwater PM, et al. (2006) Mechanism for the establishment of transcriptional HIV latency in the brain in a simian immunodeficiency virus-macaque model. J Infect Dis 193: 963-970.
21. Craigo JK, Patterson BK, Paranjpe S, Kulka K, Ding M, et al. (2004) Persistent HIV type 1 infection in semen and blood compartments in patients after longterm potent antiretroviral therapy. AIDS Res Hum Retroviruses 20: 1196-1209.
22. Fischer M, Wong JK, Russenberger D, Joos B, Opravil M, et al. (2002) Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. Antiviral Therapy 7: 91-103.
23. Lassen KG, Bailey JR, Siliciano RF (2004) Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J Virol 78: 9105-9114.
24. Hermankova M, Siliciano JD, Zhou Y, Monie D, Chadwick K, et al. (2003) Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol 77: 7383-7392.
25. Grossman Z, Polis M, Feinberg MB, Grossman Z, Levi I, et al. (1999) Ongoing HIV dissemination during HAART. Nat Med 5: 1099-1104.
26. Günthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, et al. (2000) Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 181: 522-531.
27. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, et al. (2002) HIV preferentially infects HIV-specific CD4+ T cells. Nature 417: 95-98.
28. Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV (2005) Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122: 169-182.
29. Fischer M, Hafner R, Schneider C, Trkola A, Joos B, et al. (2003) HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS 17: 195-199.
30. Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, et al. (2008) HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 105: 16725-16730.
31. Galetto-Lacour A, Yerly S, Perneger TV, Baumberger C, Hirschel B, et al. (1996) Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. Swiss HIV Cohort Study Group. J Infect Dis 173: 1388-1393.
32. Michael NL, Herman SA, Kwok S, Dreyer K, Wang J, et al. (1999) Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol 37: 2557-2563.
33. Fagard C, Lebraz M, Günthard HF, Tortajada C, Garcia F, et al. (2003) A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 163: 1220-1226.
34. Deeks SG, Walker BD (2007) Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27: 406-416.
35. Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, et al. (1999) Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 340: 1683-1684.
36. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, et al. (2000) Immune control of HIV-1 after early treatment of acute infection. Nature 407: 523-526.
37. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, et al. (2005) Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 11: 615-622.
38. Fomsgaard A, Vinner L, Therrien D, Jorgensen LB, Nielsen C, et al. (2008) Fulllength characterization of A1/D intersubtype recombinant genomes from a therapy-induced HIV type 1 controller during acute infection and his noncontrolling partner. AIDS Res Hum Retroviruses 24: 463-472.
39. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, et al. (2010) Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 201: 318-330.
40. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, et al. (2010) Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 170: 57-65.
41. Nguyen A, Calmy A, Schiffer V, Bernasconi E, Battegay M, et al. (2008) Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med 9: 142-150.
42. Lowy A, Page J, Jaccard R, Ledergerber B, Somaini B, et al. (2005) Costs of treatment of Swiss patients with HIV on antiretroviral therapy in hospital-based and general practice-based care: a prospective cohort study. AIDS Care 17: 698-710.
43. Farnham PG (2010) Do Reduced Inpatient Costs Associated with Highly Active Antiretroviral Therapy (HAART) Balance the Overall Cost for HIV Treatment? Appl Health Econ Health Policy 8: 75-88.
44. Ehrlich P (1913) Chemotherapeutics: Scientific Principles, Methods, and Results. Lancet 2: 445-451.
45. Cohn ML, Middlebrook G, Russell WF, Jr. (1959) Combined drug treatment of tuberculosis. I. Prevention of emergence of mutant populations of tubercle bacilli resistant to both streptomycin and isoniazid in vitro. J Clin Invest 38: 1349-1355.
46. Strain MC, Little SJ, Daar ES, Havlir DV, Günthard HF, et al. (2005) Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 191: 1410-1418.
47. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, et al. (2001) Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 193: 169-180.
48. Delwart E, Magierowska M, Royz M, Foley B, Peddada L, et al. (2002) Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. AIDS 16: 189-195.
49. Sagar M, Lavreys L, Baeten JM, Richardson BA, Mandaliya K, et al. (2003) Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol 77: 12921-12926.
50. Joos B, Trkola A, Fischer M, Kuster H, Rusert P, et al. (2005) Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. J Virol 79: 9026-9037.
51. Jost S, Bernard MC, Kaiser L, Yerly S, Hirschel B, et al. (2002) A patient with HIV-1 superinfection. N Engl J Med 347: 731-736.
52. Yang OO, Daar ES, Jamieson BD, Balamurugan A, Smith DM, et al. (2005) Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J Virol 79: 860-868.
53. Streeck H, Li B, Poon AF, Schneidewind A, Gladden AD, et al. (2008) Immunedriven recombination and loss of control after HIV superinfection. J Exp Med 205: 1789-1796.
54. Clerc O, Colombo S, Yerly S, Telenti A, Cavassini M (2010) HIV-1 elite controllers: Beware of super-infections. J Clin Virol 47: 376-378.
55. Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, et al. (2002) HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 420: 434-439.
56. Smith DM, Richman DD, Little SJ (2005) HIV superinfection. J Infect Dis 192: 438-444.
57. Fischer M, Joos B, Hirschel B, Bleiber G, Weber R, et al. (2004) Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef. J Infect Dis 190: 1979-1988.
58. Althaus CF, Gianella S, Rieder P, von Wyl V, Kouyos RD, et al. (2010) Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance. J Virol Methods 165: 151-160.
59. Lassen KG, Ramyar KX, Bailey JR, Zhou Y, Siliciano RF (2006) Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog 2: e68.
60. Rieder P, Joos B, von Wyl V, Kuster H, Grube C, et al. (2010) HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS.
61. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, et al. (1999) Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 340: 1614-1622.
62. Metzner KJ, Rauch P, von Wyl V, Leemann C, Grube C, et al. (2010) Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis 201: 1063-1071.
63. Fischer M, Günthard HF, Opravil M, Joos B, Huber W, et al. (2000) Residual HIV-RNA levels persist for up to 2.5 years in PBMC of patients on potent antiretroviral therapy. AIDS Res Hum Retroviruses 16: 1135-1140.
64. Otero M, Nunnari G, Leto D, Sullivan J, Wang FX, et al. (2003) Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART. AIDS Res Hum Retroviruses 19: 1097-1103.
65. Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, et al. (2009) Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One 4: e8490.
66. Guadalupe M, Sankaran S, George MD, Reay E, Verhoeven D, et al. (2006) Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 80: 8236-8247.
67. George MD, Reay E, Sankaran S, Dandekar S (2005) Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ Tcell restoration and enhanced gene expression regulating mucosal repair and regeneration. J Virol 79: 2709-2719.
68. Spina CA, Kwoh TJ, Chowers MY, Guatelli JC, Richman DD (1994) The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med 179: 115-123.
69. Feinberg MB (1996) Changing the natural history of HIV disease. Lancet 348: 239-246.
70. von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, et al. (2007) Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 167: 1782-1790.
71. Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, et al. (2006) Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med 3: e441.
72. Christopherson C, Kidane Y, Conway B, Krowka J, Sheppard H, et al. (2000) PCR-Based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells. J Clin Microbiol 38: 630-634.
73. Roscic-Mrkic B, Fischer M, Leemann C, Manrique A, Gordon CJ, et al. (2003) RANTES (CCL5) utilizes the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood 102: 1169-1177.